LENZ Therapeutics, Inc. (LENZ)

Corporate Overview

LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia. To learn more, please visit www.VIZZ.com.

Our Leadership

Latest Financial Results

Q1 2026

Quarter Ended Mar 31, 2026

Earnings Release PDF

Earnings Webcast

10-Q PDF

XBRL

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2025

Latest News

May 11, 2026 • 4:05 PM EDT

LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

View Press Release View All News

Upcoming Event

May 13 – May 14, 2026

Bank of America Global Healthcare Conference

Add to Calendar View All Events

Email Alerts

Get the latest news and reports delivered right to your inbox.

IR Contacts

Corporate

LENZ Therapeutics, Inc.
201 Lomas Santa Fe Drive
Suite 300
Solana Beach, CA 92075
T: (888) 928-LENZ (5369)
contact@lenz-tx.com

Investor Relations

LENZ Therapeutics
IR@LENZ-Tx.com

Transfer Agent

Equiniti Trust Company, LLC
48 Wall Street
New York, NY 10005
T: 800-937-5449